0001558370-23-009258 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2023	May 08, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-38869
Entity Registrant Name	HOOKIPA PHARMA INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-5395687
Entity Address, Address Line One	350 Fifth Avenue, 72nd Floor, Suite 7240
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10118
Country Region	+43
City Area Code	1
Local Phone Number	890 63 60
Title of 12(b) Security	Common Stock
Trading Symbol	HOOK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Central Index Key	0001760542
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		52,322,822
Class A common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		2,399,517

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 109,600	$ 112,488
Restricted cash		537
Accounts receivable	501	6,533
Receivable research incentives	17,962	15,479
Prepaid expenses and other current assets	11,850	12,159
Total current assets	139,913	147,196
Non-current assets:
Restricted cash	421	419
Property, plant and equipment, net	17,975	17,970
Operating lease right of use assets	3,686	4,006
Other non-current assets	1,093	863
Total non-current assets	23,175	23,258
Total assets	163,088	170,454
Current liabilities
Accounts payable	7,075	5,488
Deferred revenues	19,047	15,684
Operating lease liabilities, current	1,719	1,688
Accrued expenses and other current liabilities	14,301	11,178
Loans payable, current	2,067	1,594
Total current liabilities	44,209	35,632
Non-current liabilities
Loans payable, non-current		911
Operating lease liabilities, non-current	1,972	2,310
Deferred revenues, non-current	30,281	25,664
Other non-current liabilities	3,147	3,420
Total non-current liabilities	35,400	32,305
Total liabilities	79,609	67,937
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively; Series A convertible preferred stock, 2,978 shares designated, 1,697 shares outstanding at March 31, 2023 and December 31, 2022, respectively; Series A-1 convertible preferred stock, 15,800 shares designated, 15,800 shares outstanding at March 31, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	398,008	397,349
Accumulated other comprehensive loss	(7,173)	(7,156)
Accumulated deficit	(307,361)	(287,681)
Total stockholders' equity	83,479	102,517
Total liabilities and stockholders' equity	163,088	170,454
Common stock
Stockholders' equity:
Common stock	5	5
Class A common stock
Stockholders' equity:
Common stock	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Series A Convertible Preferred Stock
Preferred stock shares Designated	2,978	2,978
Preferred stock, shares outstanding	1,697	1,697
Series A -1 Convertible Preferred Stock
Preferred stock shares Designated	15,800	15,800
Preferred stock, shares outstanding	15,800	15,800
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	52,322,822	52,317,138
Common stock, shares outstanding	52,322,822	52,317,138
Class A common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,900,000	3,900,000
Common stock, shares issued	2,399,517	2,399,517
Common stock, shares outstanding	2,399,517	2,399,517

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
Revenue from collaboration and licensing	$ 3,176	$ 1,445
Revenue from Contract with Customer, Product and Service [Extensible List]	hook:CollaborationAndLicensingMember	hook:CollaborationAndLicensingMember
Operating expenses:
Research and development	$ (20,931)	$ (16,620)
General and administrative	(4,902)	(4,972)
Total operating expenses	(25,833)	(21,592)
Loss from operations	(22,657)	(20,147)
Other income (expense):
Grant income	2,353	1,887
Interest income	1,171	7
Interest expense	(122)	(243)
Other income and (expenses), net	(220)	528
Total other income, net	3,182	2,179
Net loss before tax	(19,475)	(17,968)
Income tax expense	(205)	0
Net loss	(19,680)	(17,968)
Other comprehensive (loss) income:
Foreign currency translation gain (loss), net of tax	(17)	(487)
Comprehensive loss	$ (19,697)	$ (18,455)
Net loss per share - basic	$ (0.27)	$ (0.40)
Net loss per share - diluted	$ (0.27)	$ (0.40)

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Convertible Preferred Stock Series A-1 convertible preferred stock	Convertible Preferred Stock	Common Stock Common stock Public offering	Common Stock Common stock Stock Purchase Agreement	Common Stock Common stock	Common Stock Class A common stock	Additional Paid-In Capital Series A-1 convertible preferred stock	Additional Paid-In Capital Public offering	Additional Paid-In Capital Stock Purchase Agreement	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Series A-1 convertible preferred stock	Public offering	Stock Purchase Agreement	Total
Balance at the beginning of the period at Dec. 31, 2021		$ 0			$ 3	$ 0				$ 317,135	$ (4,780)	$ (222,766)				$ 89,592
Balance at the beginning of the period (in shares) at Dec. 31, 2021		1,697			27,383,483	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	$ 0		$ 2	$ 0			$ 29,625	$ 40,685	$ 5,000				$ 29,625	$ 40,687	$ 5,000
Issuance of common stock (in shares)	15,800		21,700,000	1,666,666
Issuance of common stock upon exercise of stock options					$ 0					1						1
Issuance of common stock upon exercise of stock options (in shares)					10,034
Vesting of equity grants					$ 0					0
Vesting of equity grants (in shares)					112,551
ATM costs										(142)						(142)
Foreign currency translation adjustment, net of tax											(487)					(487)
Stock-based compensation expense										1,621						1,621
Net loss												(17,968)				(17,968)
Balance at the end of the period at Mar. 31, 2022		$ 0			$ 5	$ 0				393,925	(5,267)	(240,734)				147,929
Balance at the end of the period (in shares) at Mar. 31, 2022		17,497			50,872,734	3,819,732
Balance at the beginning of the period at Dec. 31, 2021		$ 0			$ 3	$ 0				317,135	(4,780)	(222,766)				89,592
Balance at the beginning of the period (in shares) at Dec. 31, 2021		1,697			27,383,483	3,819,732
Increase (Decrease) in Stockholders' Equity
Net loss																(64,900)
Balance at the end of the period at Dec. 31, 2022		$ 0			$ 5	$ 0				397,349	(7,156)	(287,681)				102,517
Balance at the end of the period (in shares) at Dec. 31, 2022		17,497			52,317,138	2,399,517
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options					$ 0					1						$ 1
Issuance of common stock upon exercise of stock options (in shares)					5,684											5,684
Foreign currency translation adjustment, net of tax											(17)					$ (17)
Stock-based compensation expense										658						658
Net loss												(19,680)				(19,680)
Balance at the end of the period at Mar. 31, 2023		$ 0			$ 5	$ 0				$ 398,008	$ (7,173)	$ (307,361)				$ 83,479
Balance at the end of the period (in shares) at Mar. 31, 2023		17,497			52,322,822	2,399,517

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares
Series A-1 convertible preferred stock
Share price (in USD per share) \| $ / shares	$ 2,000
Issuance costs \| $	$ 1,975
Common stock \| Public offering
Share price (in USD per share) \| $ / shares	$ 2.00
Issuance costs \| $	$ 2,713
Common stock \| Stock Purchase Agreement
Share price (in USD per share) \| $ / shares	$ 3.00
Issuance costs \| $	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (19,680)	$ (17,968)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	658	1,621
Depreciation and amortization expense	921	1,078
Other non-cash items	4	74
Changes in operating assets and liabilities:
Accounts receivable	6,139	6,075
Receivable research incentives	(2,202)	(1,655)
Prepaid expenses and other current assets	407	756
Other non-current assets	(214)	(460)
Accounts payable	1,557	(1,614)
Deferred revenues	7,213	14,128
Operating lease liabilities	(377)	(421)
Accrued expenses and other liabilities	2,933	9
Other non-current liabilities	(207)	110
Net cash (used in) provided by operating activities	(2,848)	1,733
Investing activities:
Purchases of property and equipment	(274)	(1,828)
Net cash used in investing activities	(274)	(1,828)
Financing activities:
Payments related to finance leases		(20)
Proceeds from issuance of convertible preferred stock, net of issuance costs		29,625
Proceeds from issuance of common stock, net of issuance costs	1	45,688
Payments for deferred offering costs	(139)
Repayments of borrowings	(597)	0
Net cash (used in) provided by financing activities	(735)	75,293
Net (decrease) increase in cash, cash equivalents and restricted cash	(3,857)	75,198
Cash, cash equivalents and restricted cash at beginning of period	113,444	66,912
Effect of exchange rate changes on cash, cash equivalents and restricted cash	434	(307)
Cash, cash equivalents and restricted cash at end of period	110,021	141,803
Supplemental disclosure of cash flow information:
Cash paid for interest	(1)
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing activities:
Property and equipment additions in accounts payable and accrued expenses	$ 22	(504)
Lease assets obtained in exchange for new operating lease liabilities		$ 240

Nature of the business and organization

3 Months Ended

Mar. 31, 2023

Nature of the business and organization

Nature of the business and organization

1. Nature of the business and organization

HOOKIPA Pharma Inc. (“HOOKIPA” or the “Company”) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

The Company was incorporated under the name of Hookipa Biotech, Inc. under the laws of the State of Delaware in February 2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June 2018, the Company changed its name from Hookipa Biotech, Inc. to HOOKIPA Pharma Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April 2019, the Company closed its initial public offering (“IPO”) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol “HOOK”.

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company’s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.

Summary of significant accounting policies

3 Months Ended

Mar. 31, 2023

Summary of significant accounting policies

Summary of significant accounting policies

2. Summary of significant accounting policies

Basis of presentation

The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

The consolidated balance sheet as of December 31, 2022 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations, and comprehensive loss for the three months ended March 31, 2023 and 2022, the condensed consolidated statement of convertible preferred stock and stockholders’ equity for the three months ended March 31, 2023 and 2022 and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement for interim reporting. Certain information and footnote disclosures typically included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission. The results for any interim period are not necessarily indicative of results for any future period. Certain previous year amounts have been reclassified to conform to the current year presentation.

Going concern

Since inception, the Company’s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through March 31, 2023, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $19.7 million for the three months ended March 31, 2023 and $64.9 million for the year ended December 31, 2022. As of March 31, 2023, the Company had an accumulated deficit of $307.4 million. The Company expects to continue to generate operating losses in the foreseeable future. As of May 11, 2023, the filing date of this Quarterly Report on Form 10-Q, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12 months from the issuance date of the condensed consolidated financial statements.

The Company will seek additional funding in order to reach its development and commercialization objectives. The Company may seek funds through further equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.

The COVID-19 pandemic continues to affect economies and business around the world. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact the developments, trends and expectations described below. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.

Deferred offering costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss.

Concentrations of credit risk and of significant suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the three months ended March 31, 2023 and March 31, 2022 the net proceeds from the Company’s offerings have been deposited in interest-bearing bank accounts with two of the largest investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of March 31, 2023 and December 31, 2022, the Company’s cash and cash equivalents included smaller amounts of cash balances held in accounts with regional European banks at the Company’s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.

As of March 31, 2023 and December 31, 2022, Gilead Sciences, Inc. (“Gilead”) and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together “Roche”) accounted for the majority of the accounts receivable balance. For the three months ended March 31, 2023 and the three month ended March 31, 2022 Gilead and Roche accounted for the majority of the Company’s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.

Cash equivalents

The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of March 31, 2023 and December 31, 2022, cash equivalents consisted of money market funds and short-term deposits.

Fair value measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

●

Level 1 - Quoted prices in active markets for identical assets or liabilities.

●

Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

●

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 4).

Property and equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:


		Estimated useful life
Leasehold improvements		shorter of useful life or term of lease
Laboratory equipment		2 - 10 years
Furniture and fixtures		2 - 10 years
Computer equipment and software		2 - 4 years

Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.

Leases

The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (“ROU”) assets and lease liabilities in the consolidated balance sheets. For leases with an initial term of 12 months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of

inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company’s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification (“ASC”) 360.

Capitalized Software Development Cost

The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC 350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals.

Revenue recognition from contracts with customers

The Company recognized revenue from collaboration and license agreements with Gilead and Roche.

Under the collaboration and license agreement with Gilead (as amended and restated, the “Gilead Collaboration Agreement”), the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (“HBV”) and the human immunodeficiency virus (“HIV”). In February 2022, the parties signed an amended and restated collaboration agreement (the “Restated Gilead Collaboration Agreement”), which revised the terms only for the HIV program, whereby the Company will take on development responsibilities for the HIV program candidate through a Phase 1b clinical trial. The Company’s performance obligations under the terms of the original agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The terms of the Restated Gilead Collaboration Agreement added an additional performance obligation to perform research and development work for the HIV program. The licenses do not represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under the Restated Gilead Collaboration Agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.

Under the research collaboration and license agreement with Roche (the “Roche Collaboration Agreement”), the Company has agreed to conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The Roche Collaboration Agreement also includes an obligation of the Company to deliver a specified package of preclinical data and results with respect to a second program, targeting undisclosed cancer antigens (collectively “UCAs”) and an option for Roche to license the UCA program. The Company’s performance obligations under the terms of the Roche Collaboration Agreement include one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services with respect to the UCA program. The UCA Option provides a right to license the program at the standalone selling price and therefore does not constitute a separate performance obligation. Payments to the Company under the Roche Collaboration Agreement include a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales.

The Company evaluates its collaboration and licensing arrangements pursuant to ASC 606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.

Under ASC 606, the Company applies significant judgement to evaluate whether the promises under the collaboration and licensing arrangements, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, the timing of revenue recognition, whether the UCA Option constitutes a material right, and the determination of when milestone payments are probable of being received.

Upfront payment and program initiation fee

The non-refundable upfront-payment received by the Company upon signing of the Gilead Collaboration Agreement, and milestone payments that were linked to future performance obligations, were initially recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.

The non-refundable program initiation payment received from Gilead upon signing of the Restated Collaboration Agreement was also initially recorded as deferred revenue and is recognized on a percent of completion basis using total estimated research and development costs (input method) for the performance of the obligations. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer, due to the immediate benefit that it adds to the value of the customer’s rights on the program, the short time intervals in which development results are shared and the nature of the work being performed.

The non-refundable upfront-payment received by the Company upon signing of the Roche Collaboration Agreement, was initially recorded as deferred revenue and allocated between the HB-700 program and the UCA program. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs (input method) for each of the obligations during the initial term of the contract. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer.

Reimbursement for services

Under the Gilead Collaboration Agreement and the Roche Collaboration Agreement, the Company incurs employee expenses as well as external costs for research, manufacturing and clinical trial activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangements, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues as progress is achieved. Unpaid reimbursement amounts are presented as Accounts Receivable.

Research and development milestones

The Gilead Collaboration Agreement and the Roche Collaboration Agreement include contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC 606, due to the scientific uncertainties and the required commitment from Gilead and Roche. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to including the variable consideration associated with these payments within the transaction price.

Sales-based milestones and royalty payments

The Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC 606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.

Cost to fulfill contracts

The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.

Recent accounting pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date.

Recently Issued Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the “own stock” scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.

Collaboration and Licensing Agreements

3 Months Ended

Mar. 31, 2023

Collaboration and Licensing Agreements

Collaboration and Licensing Agreements

3. Collaboration and Licensing Agreements

Gilead Collaboration and License Agreement

In June 2018, the Company entered into the Gilead Collaboration Agreement whereby the Company and Gilead agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February 2022, the Company signed the Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic. Most importantly, the Amended and Restated Collaboration Agreement allocated additional research and development responsibility to the Company with respect to the Company’s HIV candidate and provided for additional funding by Gilead of such research and development activities as well as increased later stage development and commercial milestone payments.

Under the Gilead Collaboration Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company’s technology platforms. Upon entering into the agreement in June 2018, the Company received a non-refundable $10.0 million upfront payment from Gilead and upon signing of the Restated Gilead Collaboration Agreement in February 2022, the Company received a program initiation fee of $15.0 million. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to $140.0 million for the HBV program, and up to $172.5 million for the HIV program, inclusive of a $10.0 million program completion fee, payable upon Gilead’s exercise of the option to pursue further development activities post Phase 1b. The commercial milestones amount to a total of $50.0 million for the HBV program, and $65.0 million for the HIV program. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a 60 day payment term.

The $10.0 million upfront payment, the $15.0 million initiation fee and $8.0 million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of March 31, 2023, $13.4 million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December 31, 2022, $14.3 million of upfront, initiaton and milestone payments were included as a liability in deferred revenues, current. Approximately 23% of deferred revenue is expected to be recognized as revenue in the remainder of 2023, 37% in 2024, 27% in 2025 and the remaining 13% in 2026.

In the three months ended March 31, 2023, the Company recognized $1.2 million of the milestone and initiation payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $0.5 million revenue from cost reimbursements for research and development services. In the three months ended March 31, 2022, the Company recognized $0.6 million of the upfront and milestone payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $0.8 million revenue from cost reimbursements for research and development services.

Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of March 31, 2023 and December 31, 2022, the contract asset relating to the sublicense payment was $0.2 million and $0.2 million, respectively, and there was no liability relating to sublicense payment.

Roche Collaboration and License Agreement

In October 2022, the Company entered into the Roche Collaboration Agreement whereby the Company and Roche agreed to collaborate with respect to the development of novel arenaviral immunotherapies for KRAS-mutated

cancers and, potentially, a second, novel arenaviral immunotherapeutic program targeting specific undisclosed cancer antigens.

Under the Roche Collaboration Agreement, the Company granted Roche an exclusive, royalty-bearing license to the Company’s technology platforms. Upon signing the Roche Collaboration Agreement in October 2022, the Company received a non-refundable upfront payment of $25.0 million and Roche will be obliged to pay an additional $15.0 million payment if the option for the UCA program is exercised. The Company is also eligible for event-based milestone payments of up to an aggregate of $335.0 million during the research and development phase of the HB-700 program for up to four oncology indications and up to an aggregate of $250.0 million in payments related to the achievement of sales-based milestones. For the additional UCA program, subject to option-exercise, the Company is eligible for up to an aggregate of $173.0 million in event-based milestone payments during research and development for up to four oncology indications as well as up to an aggregate of $160.0 million in sales-based milestones. Upon commercialization, the Company is eligible to receive tiered royalties on the worldwide net sales of HB-700 and, subject to option exercise, the UCA program. The royalty payments are subject to reduction under specified conditions set forth in the Roche Collaboration Agreement. Payments from Roche generally have payment terms between 30 days and 60 days.

The $25.0 million upfront payment, and a $10.0 million milestone payment received in the three months ended March 31, 2023 were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of March 31, 2023, $35.9 million of such payments were still recorded as a liability in deferred revenues, current and non-current. The deferred revenues related to the $25.0 million upfront payment and the $10.0 million milestone payment are subject to foreign currency exchange rate fluctuations in future accounting periods. Approximately 36% of deferred revenue is expected to be recognized as revenue in the remainder of 2023, 19% in 2024, 18% in 2025, 17% in 2026 and the remaining 10% in 2027.

In the three months ended March 31, 2023, the Company recognized $1.5 million of the upfront and milestone payments that were originally recorded as deferred revenue.

Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of March 31, 2023 the contract asset and the liability relating to the sublicense payment was $2.3 million and $2.1 million, respectively. As of December 31, 2022 the contract asset and the liability relating to the sublicense payment was $1.5 million and $1.2 million, respectively.

Fair Value of Financial Assets

3 Months Ended

Mar. 31, 2023

Fair Value of Financial Assets

Fair Value of Financial Assets

4. Fair Value of Financial Assets

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):


	Fair Value Measurement at March 31, 2023 Using
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	81,452	$	—	$	—	$	81,452
Total	$	81,452	$	—	$	—	$	81,452


	Fair Value Measurement at December 31, 2022 Using
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	85,491	$	—	$	—	$	85,491
Total	$	85,491	$	—	$	—	$	85,491

During the three months ended March 31, 2023, there were no transfers between Level 1, Level 2 and Level 3.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property, plant and equipment, net

3 Months Ended

Mar. 31, 2023

Property, plant and equipment, net.

Property, plant and equipment, net

5. Property, plant and equipment, net

Property, plant and equipment, net consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022

Land	$	1,990	$	1,959
Leasehold improvements		3,229		3,164
Construction in progress		10,203		10,567
Laboratory equipment		8,244		7,403
Furniture and fixtures		637		622
Computer equipment and software		2,100		2,034
Property and equipment, gross		26,403		25,749
Less: Accumulated depreciation		(8,428)		(7,779)
Property and equipment, net	$	17,975	$	17,970

Construction-in-progress as of March 31, 2023 and December 31, 2022 mainly related to investments in connection with the Company’s GMP manufacturing facility project.

Receivable research incentive

3 Months Ended

Mar. 31, 2023

Receivable research incentive

Receivable research incentive

6. Receivable research incentive

The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.

As of March 31, 2023, the Company recognized receivables of $18.0 million from the research incentive program, which are reported in research incentive receivables in the Company’s condensed consolidated balance sheet. As of December 31, 2022, the receivables from the research incentive program were $15.5 million.

During the three months ended March 31, 2023 and 2022, the Company recorded $2.2 million and $1.7 million, respectively, of income related to the incentive program within the Company’s condensed consolidated statements of operations as part of the grant income. Research incentives depend on the eligible research and development expenses of the respective period.

Accrued expenses and other current liabilities

3 Months Ended

Mar. 31, 2023

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

7. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Salaries and bonuses		3,931		4,481
Social security contributions		369		267
Unearned grant income (current)		237		300
Sublicense fees		2,089		1,220
Accrued external research and development expenses		6,138		3,458
Accrued external general and administration expenses		543		898
Income taxes		402		230
Other accruals and liabilities		592		324
	$	14,301	$	11,178

Loans payable

3 Months Ended

Mar. 31, 2023

Loans payable

Loans payable

8. Loans payable

As of March 31, 2023 and December 31, 2022, loans payable consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Loans from FFG	$	2,305	$	2,855
Unamortized debt discount		(238)		(350)
Total loans payable, net	$	2,067	$	2,505

In connection with the funding agreements with the Austrian Research Promotion Agency, (Österreichische Forschungsförderungsgesellschaft, or “FFG”), the Company has received various loans (“FFG Loans”). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of 0.75% per annum and mature at various dates between June 2023 and March 2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.

The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.

A principal repayment of $0.6 million was made in the three months ended March 31, 2023. No principal repayment was made in the three months ended March 31, 2022.

As of March 31, 2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):


Payments Due by Calendar Year	Amount
2023 (remaining 9 months)		1,153
2024		1,152
2025		—
2026		—
2027		—
Thereafter		—
Total	$	2,305

Common stock, Class A common stock and convertible preferred stock

3 Months Ended

Mar. 31, 2023

Common stock, Class A common stock and convertible preferred stock

Common stock, Class A common stock and convertible preferred stock

9. Common stock, Class A common stock and convertible preferred stock

The Company’s capital structure consists of common stock, Class A common stock and preferred stock. As of March 31, 2023, the Company was authorized to issue 200,000,000 shares of common stock, 3,900,000 shares of Class A common stock and 10,000,000 shares of preferred stock. The Company has designated 2,978 of the 10,000,000 authorized shares of preferred stock as non-voting Series A convertible preferred stock and 15,800 of the 10,000,000 authorized shares of preferred stock as non-voting Series A-1 convertible preferred stock. As of March 31, 2023, the Company had 52,322,822 shares of common stock, 2,399,517 shares of Class A common stock, 1,697 shares of Series A convertible preferred stock and 15,800 shares of Series A-1 convertible preferred stock outstanding and issued.

In July 2022 and August 2022 certain of the Company’s stockholders elected to convert an aggregate of 1,420,215 shares (769,734 and 650,481 shares, respectively) of Class A common stock owned by such holders into an aggregate of 1,420,215 shares of the Company’s common stock.

On February 15, 2022, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Gilead, that requires Gilead, at the Company’s option, to purchase up to $35.0 million of the Company’s common stock. On February 15, 2022, Gilead purchased an initial amount of 1,666,666 shares of the Company’s common stock in exchange for $5.0 million in cash at a purchase price per share equal to $3.00. Pursuant to the terms of the Stock Purchase Agreement, the Company may require Gilead to purchase the balance of the $30.0 million of common stock, at the discretion of the Company, in one or two subsequent purchases at a price equal to the volume weighted average purchase price preceding such purchase, as defined in the Stock Purchase Agreement, plus, for the first subsequent purchase, which can be up to the full $30.0 million balance, a premium of 30%. The Company’s right to sell shares of its common stock to Gilead is subject to specified limitations, including a limitation that prevents the Company from requesting purchases of shares of common stock by Gilead that would result in a beneficial ownership of more than 19.9% of the total number of outstanding shares of common stock by Gilead. At March 31, 2023, this limitation would have prevented the Company from requesting that Gilead purchase the full remaining $30.0 million balance of the investment commitment. The Company agreed to file a registration statement on Form S-3 to register for resale any additional shares of common stock issued to Gilead within four months from issuance.

On March 4, 2022, the Company closed a public offering of 21,700,000 shares of its common stock and of 15,800 shares of Series A-1 convertible preferred stock at a public offering price of $2.00 and $2,000.00 per share, respectively, for net proceeds of $70.2 million after deducting underwriting discounts and commissions and offering expenses including pro-rata ATM expenses.

The Company has two series of preferred stock authorized, issued and outstanding as of March 31, 2023: Series A convertible preferred stock and Series A-1 convertible preferred stock. Shares of Series A and Series A-1

convertible preferred stock may be independently converted into common stock. Holders of Series A and Series A-1 convertible preferred stock have equal rights, powers and privileges.

Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class A common stock and Series A and Series A-1 convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.

Each holder of Class A common stock has the right to convert each share of Class A common stock into one share of common stock at such holder's election. Each holder of Series A and Series A-1 convertible preferred stock has the right to convert each share of Series A and Series A-1 convertible preferred stock into 1,000 shares of common stock at any time at the holder’s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A and Series A-1 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding.

Holders of common stock and Class A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series A and Series A-1 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of the Company’s common stock. Holders of common stock and Class A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.

In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series A and Series A-1 preferred stock will receive a payment equal to $0.001 per share of Series A and Series A-1 preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.

There were 1,697 shares of Series A convertible preferred stock and 15,800 shares of Series A-1 convertible preferred stock outstanding as of March 31, 2023 and December 31, 2022, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock-based compensation

3 Months Ended

Mar. 31, 2023

Stock-based compensation

Stock-based compensation

10. Stock-based compensation

2018 Stock Option and Grant Plan

In June 2018, the Board of Directors approved the 2018 Stock Option and Grant Plan. Options granted under the 2018 Stock Option and Grant Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10^th anniversary of the grant date. As of March 31, 2023, 895,112 options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.

2019 Stock Option and Incentive Plan

On April 1, 2019, the Company’s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company’s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. As of March 31 2023, the maximum number of shares of the Company’s common stock that may be issued

under the Company’s 2019 Stock Option and Incentive Plan was 8,067,480 shares which shall be cumulatively increased each year by up to 4.0% of the then outstanding number of shares of common stock and Class A common stock. Options granted under the 2019 Stock Option and Incentive Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a three-year term with 33% of the options vesting upon the first anniversary of the grant date and the remaining 67% of the options vesting in eight equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10^th anniversary of the grant date. For each option, the beneficiary is entitled to receive one share of common stock upon the exercise of the option.

Stock option valuation

The Company estimates the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S. Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.

The following table summarizes the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:


	Three months ended March 31,
	2023		2022

Risk-free interest rate	—	%	1.64	%
Expected term (in years)	—		5.0
Expected volatility	—	%	85.8	%
Expected dividends	—	%	—	%

For the 2022 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.

Stock option activity

The following table summarizes the Company’s stock option activity since January 1, 2023 (in thousands, except share and per share amounts):


				Weighted
		Weighted		Average
		Average		Remaining	Aggregate
	Number of	Exercise		Contractual	Intrinsic
	Shares	Price		Term	Value
				(in years)
Outstanding as of December 31, 2022	6,532,523	$	6.19	7.7	$	490
Granted	—		—
Exercised	(5,684)		0.10
Forfeited	(43,527)		6.13
Outstanding as of March 31, 2023	6,483,312	$	6.20	7.4	$	435

Options exercisable as of March 31, 2023	3,779,107	$	7.85	6.4	$	435
Options unvested as of March 31, 2023	2,704,205	$	3.88	8.8	$	—

The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The fair value per common stock used for calculating the intrinsic values as of March 31, 2023 and December 31, 2022, was $0.74 and $0.81, respectively.

Cash received from stock option exercise under share-based payment arrangements for the three months ended March 31, 2023 and March 31, 2022 was $1 thousand, respectively.

Common Stock Awards

In the three months ended March 31, 2022 the Company issued unrestricted shares of common stock to its executive team. The Company’s executive team agreed to convert a portion of their base salaries, for the six months ended June 30, 2022, for shares of the Company’s fully vested common stock having a value equal to their foregone salary, determined based on a value of $3.00 per share, resulting in the issuance of 112,551 shares of common stock in the three months ended March 31, 2022. The total fair value of common stock awards issued during the three months ended March 31, 2022 was $0.2 million. The grant date fair value per share of common stock was $1.50 and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the three months ended March 31, 2022. No unrestricted shares of common stock were issued in the three months ended March 31, 2023.

Stock-based compensation

Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):


	Three months ended March 31,
	2023		2022
Research and development expenses	$	240	$	618
General and administrative expenses		418		1,003
	$	658	$	1,621

Income taxes

3 Months Ended

Mar. 31, 2023

Income taxes

Income taxes

11. Income taxes

Income tax expense during the three months ended March 31, 2023 and 2022, resulted from U.S. federal and state income tax as well as minimum tax obligations in Austria. Income tax expense during the three months ended March 31, 2022 resulted from minimum tax obligations in Austria. During the three months ended March 31, 2023 and 2022, the Company recorded no income tax benefits for the net operating losses incurred, due to its uncertainty of realizing a benefit from those items. The Company’s losses before income taxes were generated in the United States and Austria. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets resulting from its net operating loss carryforwards. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of March 31, 2023 and December 31, 2022. Management reevaluates the positive and negative evidence at each reporting period.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Commitments and contingencies

3 Months Ended

Mar. 31, 2023

Commitments and contingencies

Commitments and contingencies

12. Commitments and contingencies

Operating and Finance Leases

The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company is required to maintain a cash balance of $0.4 million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the Company’s condensed consolidated balance sheet as of March 31, 2023.

As of March 31, 2023 and December 31, 2022, the Company’s operating lease right-of-use assets were $3.7 million and $4.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company had outstanding operating lease obligations of $3.7 million, of which $1.7 million is reported in operating lease liabilities, current portion and $2.0 million is reported in operating lease liabilities, non-current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $4.0 million, of which $1.7 million is reported in operating lease liabilities, current portion and $2.3 million is reported in operating lease liabilities, non-current portion in the Company’s condensed consolidated balance sheets. The Company’s weighted average discount rate and weighted average lease term remaining on operating lease liabilities is approximately 1.3% and 2.5 years, respectively.

Contract manufacturing arrangements

The Company has entered into arrangements with contract manufacturing organizations (“CMOs”) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of March 31, 2023, the Company’s total non-cancellable obligations under contracts with CMOs were $8.8 million, of which $8.6 million relate to 2023 (remaining nine months) deliverables, and $0.2 million relate to 2024 deliverables.

Intellectual property licenses

The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.

In the three months ended March 31, 2023, the Company recorded $0.3 million in licensing fees related to intellectual property licenses as research and development expenses. The amount is mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement and the Roche Collaboration Agreement. The amount recognized as expenses has been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.

Indemnification agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2023 or December 31, 2022.

Legal proceedings

At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently a party to a patent proceeding opposing European Patent No. 3218504, which was granted to the University of Geneva in July 2020 and is exclusively licensed to the Company. While it is not feasible to predict the outcome of these matters with certainty, and some lawsuits, claims or proceedings may be disposed or decided unfavorably, the Company does not expect that the pending patent opposition, and any asserted or unasserted legal claims or proceedings, individually or in the aggregate, will have a material adverse effect on the Company. However, if, as a result of the current patent proceeding, the Company would lose all, or at least part, of the protection under the opposed patent, such loss could erode the Company’s competitive position and harm its business and ability to achieve profitability. The Company expenses the costs related to the pending and other such legal proceedings as incurred.

Net loss per share

3 Months Ended

Mar. 31, 2023

Net loss per share

Net loss per share

13. Net loss per share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):


	Three months ended March 31,
	2023		2022
Numerator:
Net loss	$	(19,680)	$	(17,968)

Denominator:
Weighted-average common shares outstanding, basic and diluted		54,720,823		38,603,022
Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock⁽¹⁾		1,697,000		1,697,000
Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock⁽¹⁾		15,800,000		4,740,000
Total number of shares used to calculate net loss per share, basic and diluted		72,217,823		45,040,022

Net loss per share, basic and diluted	$	(0.27)	$	(0.40)

⁽¹⁾ Class A common stock, Series A and Series A-1 convertible preferred stock are participating securities that have substantially the same terms and features as the Company’s common stock. The Class A common stock, Series A and Series A-1 convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Class A common stock, Series A and Series A-1 convertible preferred stock is independently convertible into one and 1,000 shares of common stock, respectively. 2,399,517 shares of the Company’s common stock are issuable upon conversion of the Class A common stock, 1,697,000 shares of the Company’s common stock are issuable upon conversion of Series A convertible preferred stock and 15,800,000 shares of the Company’s common stock are issuable upon conversion of Series A-1 convertible preferred stock (see Note 9).

Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (common stock and Class A common stock) outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:


	Three months ended March 31,
	2023	2022
Options issued and outstanding	6,483,312	4,298,946
Unvested restricted stock units	—	—
Total	6,483,312	4,298,946

Subsequent Events

3 Months Ended

Mar. 31, 2023

Subsequent Events

Subsequent Events

14. Subsequent Events

Stock option grant

In April 2023, the Company granted stock options to purchase 2,102,100 shares of common stock at an exercise price of $1.00 per share option to employees. All options granted vest over four years, with 25% of the options vesting on February 15, 2024 and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the vesting date, provided the option holder continues to have an employment relationship with the Company on each vesting date. In addition, in April 2023, the Company’s board approved the HOOKIPA Pharma Inc. 2023 Inducement Plan and reserved 500,000 shares of common stock for stock options issued as inducement grants to new employees.

Summary of significant accounting policies (Policies)

3 Months Ended

Mar. 31, 2023

Summary of significant accounting policies

Basis of presentation

Going concern

Use of estimates

Deferred offering costs

Concentrations of credit risk and of significant suppliers

Cash equivalents

Fair value measurements

●

Level 1 - Quoted prices in active markets for identical assets or liabilities.

●

The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 4).

Property and equipment


		Estimated useful life
Leasehold improvements		shorter of useful life or term of lease
Laboratory equipment		2 - 10 years
Furniture and fixtures		2 - 10 years
Computer equipment and software		2 - 4 years

Leases

Capitalized Software Development Cost

Revenue recognition from contracts with customers

The Company recognized revenue from collaboration and license agreements with Gilead and Roche.

Upfront payment and program initiation fee

Reimbursement for services

Research and development milestones

Sales-based milestones and royalty payments

Cost to fulfill contracts

Recent accounting pronouncements

Recently Issued Accounting Pronouncements

Summary of significant accounting policies (Tables)

3 Months Ended

Mar. 31, 2023

Summary of significant accounting policies

Schedule of estimated useful life of each asset


		Estimated useful life
Leasehold improvements		shorter of useful life or term of lease
Laboratory equipment		2 - 10 years
Furniture and fixtures		2 - 10 years
Computer equipment and software		2 - 4 years

Fair Value of Financial Assets (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value of Financial Assets

Schedule of financial assets measured at fair value on a recurring basis


	Fair Value Measurement at March 31, 2023 Using
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	81,452	$	—	$	—	$	81,452
Total	$	81,452	$	—	$	—	$	81,452


	Fair Value Measurement at December 31, 2022 Using
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	85,491	$	—	$	—	$	85,491
Total	$	85,491	$	—	$	—	$	85,491

Property, plant and equipment, net (Tables)

3 Months Ended

Mar. 31, 2023

Property, plant and equipment, net.

Schedule of property, plant and equipment, net

Property, plant and equipment, net consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022

Land	$	1,990	$	1,959
Leasehold improvements		3,229		3,164
Construction in progress		10,203		10,567
Laboratory equipment		8,244		7,403
Furniture and fixtures		637		622
Computer equipment and software		2,100		2,034
Property and equipment, gross		26,403		25,749
Less: Accumulated depreciation		(8,428)		(7,779)
Property and equipment, net	$	17,975	$	17,970

Accrued expenses and other current liabilities (Tables)

3 Months Ended

Mar. 31, 2023

Accrued expenses and other current liabilities

Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Salaries and bonuses		3,931		4,481
Social security contributions		369		267
Unearned grant income (current)		237		300
Sublicense fees		2,089		1,220
Accrued external research and development expenses		6,138		3,458
Accrued external general and administration expenses		543		898
Income taxes		402		230
Other accruals and liabilities		592		324
	$	14,301	$	11,178

Loans payable (Tables)

3 Months Ended

Mar. 31, 2023

Loans payable

Schedule of loans payable

As of March 31, 2023 and December 31, 2022, loans payable consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Loans from FFG	$	2,305	$	2,855
Unamortized debt discount		(238)		(350)
Total loans payable, net	$	2,067	$	2,505

Schedule of aggregate minimum future principal payments due in connection with the FFG Loans

As of March 31, 2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):


Payments Due by Calendar Year	Amount
2023 (remaining 9 months)		1,153
2024		1,152
2025		—
2026		—
2027		—
Thereafter		—
Total	$	2,305

Stock-based compensation (Tables)

3 Months Ended

Mar. 31, 2023

Stock-based compensation

Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options


	Three months ended March 31,
	2023		2022

Risk-free interest rate	—	%	1.64	%
Expected term (in years)	—		5.0
Expected volatility	—	%	85.8	%
Expected dividends	—	%	—	%

Schedule of summary of stock option activity

The following table summarizes the Company’s stock option activity since January 1, 2023 (in thousands, except share and per share amounts):


				Weighted
		Weighted		Average
		Average		Remaining	Aggregate
	Number of	Exercise		Contractual	Intrinsic
	Shares	Price		Term	Value
				(in years)
Outstanding as of December 31, 2022	6,532,523	$	6.19	7.7	$	490
Granted	—		—
Exercised	(5,684)		0.10
Forfeited	(43,527)		6.13
Outstanding as of March 31, 2023	6,483,312	$	6.20	7.4	$	435

Options exercisable as of March 31, 2023	3,779,107	$	7.85	6.4	$	435
Options unvested as of March 31, 2023	2,704,205	$	3.88	8.8	$	—

Schedule of stock-based compensation expense

Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):


	Three months ended March 31,
	2023		2022
Research and development expenses	$	240	$	618
General and administrative expenses		418		1,003
	$	658	$	1,621

Net loss per share (Tables)

3 Months Ended

Mar. 31, 2023

Net loss per share

Schedule of basic and diluted net loss per share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):


	Three months ended March 31,
	2023		2022
Numerator:
Net loss	$	(19,680)	$	(17,968)

Denominator:
Weighted-average common shares outstanding, basic and diluted		54,720,823		38,603,022
Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock⁽¹⁾		1,697,000		1,697,000
Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock⁽¹⁾		15,800,000		4,740,000
Total number of shares used to calculate net loss per share, basic and diluted		72,217,823		45,040,022

Net loss per share, basic and diluted	$	(0.27)	$	(0.40)

Schedule of potentially dilutive securities that were not included in the diluted per share calculations


	Three months ended March 31,
	2023	2022
Options issued and outstanding	6,483,312	4,298,946
Unvested restricted stock units	—	—
Total	6,483,312	4,298,946

Summary of significant accounting policies - Going concern (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Summary of significant accounting policies
Net losses	$ (19,680)	$ (17,968)	$ (64,900)
Accumulated deficit	$ (307,361)		$ (287,681)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Summary of significant accounting policies - Property and equipment (Details)	3 Months Ended
	Mar. 31, 2023
Laboratory equipment \| Minimum
Property and equipment
Estimated useful life (in years)	2 years
Laboratory equipment \| Maximum
Property and equipment
Estimated useful life (in years)	10 years
Furniture and fixtures \| Minimum
Property and equipment
Estimated useful life (in years)	2 years
Furniture and fixtures \| Maximum
Property and equipment
Estimated useful life (in years)	10 years
Computer equipment and software \| Minimum
Property and equipment
Estimated useful life (in years)	2 years
Computer equipment and software \| Maximum
Property and equipment
Estimated useful life (in years)	4 years

Summary of significant accounting policies - Others (Details)	3 Months Ended
	Mar. 31, 2023 item Program
Summary of significant accounting policies
Number of preclinical research programs \| Program	2
Number of Combined Performance Obligation	1
Number of combined performance obligation for each research program	1
Number of research program performance obligations	2

Collaboration and Licensing Agreements (Details) $ in Thousands	1 Months Ended		3 Months Ended
	Oct. 31, 2022 USD ($) item	Jun. 30, 2018 USD ($) item	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Collaboration and Licensing Agreements
Deferred revenues			$ 19,047		$ 15,684
Gilead Collaboration and License Agreement
Collaboration and Licensing Agreements
Number of preclinical research programs \| item		2
Upfront payment received		$ 10,000
Program initiation fee		$ 15,000
Payment term (in days)		60 days
Milestone payment received		$ 8,000
Percentage of upfront payment included in deferred revenue expected to be recognized in 2023			23.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2024			37.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2025			27.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2026			13.00%
Revenue recognized from milestone payments			$ 1,200	$ 600
Revenue recognized from cost reimbursements for research and development services			500	$ 800
Contract asset relating to the sublicense payment			200		200
Contract liability relating to sublicense payment			0		0
Deferred revenues					14,300
Deferred income			13,400
Roche collaboration agreement
Collaboration and Licensing Agreements
Upfront payment received	$ 25,000		25,000
Milestone payment received			$ 10,000
Percentage of upfront payment included in deferred revenue expected to be recognized in 2023			36.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2024			19.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2025			18.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2026			17.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2027			10.00%
Revenue recognized from milestone payments			$ 1,500
Contract asset relating to the sublicense payment			2,300		1,500
Contract liability relating to sublicense payment			2,100		$ 1,200
Deferred income			$ 35,900
Roche collaboration agreement \| Minimum
Collaboration and Licensing Agreements
Payment term (in days)	30 days
Roche collaboration agreement \| Maximum
Collaboration and Licensing Agreements
Payment term (in days)	60 days
CTA program
Collaboration and Licensing Agreements
Additional payments on exercise of option	$ 15,000
Event based milestone payments	$ 173,000
Number of oncology indications \| item	4
Sales based milestone payments	$ 160,000
HB 700 program
Collaboration and Licensing Agreements
Event based milestone payments	$ 335,000
Number of oncology indications \| item	4
Sales based milestone payments	$ 250,000
Development Milestones \| HBV program
Collaboration and Licensing Agreements
Total milestone amount		140,000
Development Milestones \| HIV program
Collaboration and Licensing Agreements
program completion fee		10,000
Development Milestones \| HIV program \| Maximum
Collaboration and Licensing Agreements
Total milestone amount		172,500
Commercial Milestones \| HBV program
Collaboration and Licensing Agreements
Total milestone amount		50,000
Commercial Milestones \| HIV program
Collaboration and Licensing Agreements
Total milestone amount		$ 65,000

Fair Value of Financial Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value of Financial Assets
Transfers from Level 1 to Level 2	$ 0
Transfers from Level 2 to Level 1	0
Transfers from into Level 3	0
Transfers from out of Level 3	0
Recurring
Fair Value of Financial Assets
Total	81,452	$ 85,491
Recurring \| Money market funds
Fair Value of Financial Assets
Cash equivalents	81,452	85,491
Recurring \| Level 1
Fair Value of Financial Assets
Total	81,452	85,491
Recurring \| Level 1 \| Money market funds
Fair Value of Financial Assets
Cash equivalents	$ 81,452	$ 85,491

Property, plant and equipment, net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property and equipment
Property and equipment, gross	$ 26,403	$ 25,749
Less: Accumulated depreciation	(8,428)	(7,779)
Property and equipment, net	17,975	17,970
Land
Property and equipment
Property and equipment, gross	1,990	1,959
Leasehold improvements
Property and equipment
Property and equipment, gross	3,229	3,164
Construction in progress
Property and equipment
Property and equipment, gross	10,203	10,567
Laboratory equipment
Property and equipment
Property and equipment, gross	8,244	7,403
Furniture and fixtures
Property and equipment
Property and equipment, gross	637	622
Computer equipment and software
Property and equipment
Property and equipment, gross	$ 2,100	$ 2,034

Receivable research incentive (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Receivable research incentive
Receivable research incentive	$ 17,962		$ 15,479
Income related to the incentive program recorded as grant income	$ 2,200	$ 1,700

Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued expenses and other current liabilities
Salaries and bonuses	$ 3,931	$ 4,481
Social security contributions	369	267
Unearned grant income (current)	237	300
Sublicense fees	2,089	1,220
Accrued external research and development expenses	6,138	3,458
Accrued external general and administration expenses	543	898
Income taxes	402	230
Other accruals and liabilities	592	324
Total	$ 14,301	$ 11,178

Loans payable (Details) - USD ($) $ in Thousands	3 Months Ended
Loans payable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Loans payable
Loans from FFG	$ 2,305		$ 2,855
Unamortized debt discount	(238)		(350)
Total loans payable, net	$ 2,067		$ 2,505
Interest rate (as a percent)	0.75%
Principal payment	$ 597	$ 0

Loans payable - Schedule of aggregate minimum future principal payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2023 (remaining 9 months)	$ 1,153
2024	1,152
Total	$ 2,305

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Common stock, Class A common stock and convertible preferred stock (Details) $ / shares in Units, $ in Thousands				1 Months Ended		2 Months Ended	3 Months Ended
	Mar. 31, 2023 USD ($) Vote $ / shares shares	Mar. 04, 2022 USD ($) $ / shares shares	Feb. 15, 2022 USD ($) $ / shares shares	Aug. 31, 2022 shares	Jul. 31, 2022 shares	Aug. 31, 2022 shares	Mar. 31, 2023 USD ($) Vote $ / shares shares	Mar. 31, 2022 USD ($) $ / shares	Dec. 31, 2022 shares
Preferred stock, shares authorized	10,000,000						10,000,000		10,000,000
Net proceeds from public offering \| $		$ 70,200
Proceeds from issuance of common stock, net of issuance costs \| $							$ 1	$ 45,688
Register for resale of common stock			4 months
Common stock
Common stock, shares authorized	200,000,000						200,000,000		200,000,000
Common stock, issued (in shares)	52,322,822						52,322,822		52,317,138
Common stock, outstanding (in shares)	52,322,822						52,322,822		52,317,138
Issuance of common stock		21,700,000
Share Price \| $ / shares		$ 2.00
Number of votes \| Vote	1						1
Number of shares elected to convert						1,420,215
Class A common stock
Common stock, shares authorized	3,900,000						3,900,000		3,900,000
Common stock, issued (in shares)	2,399,517						2,399,517		2,399,517
Common stock, outstanding (in shares)	2,399,517						2,399,517		2,399,517
Number of common stock issued upon conversion of each share							1
Number of shares elected to convert				650,481	769,734	1,420,215
Series A Convertible Preferred Stock
Preferred stock shares Designated	2,978						2,978		2,978
Preferred stock, shares issued	1,697						1,697
Preferred stock, shares outstanding	1,697						1,697		1,697
Series A -1 Convertible Preferred Stock
Preferred stock shares Designated	15,800						15,800		15,800
Preferred stock, shares issued	15,800						15,800
Preferred stock, shares outstanding	15,800						15,800		15,800
Issuance of common stock		15,800
Share Price \| $ / shares		$ 2,000.00
Series A and Series A-1 convertible preferred stock
Number of common stock issued upon conversion of each share							1,000
Threshold percentage for conversion	9.99%						9.99%
Liquidation preference per share \| $ / shares	$ 0.001						$ 0.001
Stock Purchase Agreement
Net proceeds from public offering \| $			$ 35,000
Issuance of common stock			1,666,666
Proceeds from issuance of common stock, net of issuance costs \| $			$ 5,000
Share Price \| $ / shares			$ 3.00
Outstanding amount \| $	$ 30,000		$ 30,000
Percentage of premium			30.00%
Stock Purchase Agreement \| Gilead \| Gilead Collaboration and License Agreement
Ownership percentage			19.90%
Stock Purchase Agreement \| Common stock
Share Price \| $ / shares								$ 3.00

Stock-based compensation - 2018 Stock Option and Grant Plan (Details)	3 Months Ended
	Mar. 31, 2023 installment shares	Dec. 31, 2022 shares
Stock-based compensation
Options outstanding	6,483,312	6,532,523
2018 Stock Option and Grant Plan
Stock-based compensation
Vesting period	4 years
Options outstanding	895,112
2018 Stock Option and Grant Plan \| Vesting upon first anniversary
Stock-based compensation
Percentage of options vesting	25.00%
2018 Stock Option and Grant Plan \| Vesting in equal quarterly installments
Stock-based compensation
Percentage of options vesting	75.00%
Number of quarterly installments for vesting \| installment	12

Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)	3 Months Ended
	Mar. 31, 2023 installment shares
Stock-based compensation
Number of common stock entitled for each option upon the exercise of the option \| shares	1
2019 Stock Option and Incentive Plan
Stock-based compensation
Number stock option authorized \| shares	8,067,480
Number of shares outstanding were cumulatively increased	4.00%
Vesting period	4 years
2019 Stock Option and Incentive Plan \| Non Executive Directors
Stock-based compensation
Vesting period	3 years
2019 Stock Option and Incentive Plan \| Vesting upon first anniversary
Stock-based compensation
Percentage of options vesting	25.00%
2019 Stock Option and Incentive Plan \| Vesting upon first anniversary \| Non Executive Directors
Stock-based compensation
Percentage of options vesting	33.00%
2019 Stock Option and Incentive Plan \| Vesting in equal quarterly installments
Stock-based compensation
Percentage of options vesting	75.00%
Number of quarterly installments for vesting \| installment	12
2019 Stock Option and Incentive Plan \| Vesting in equal quarterly installments \| Non Executive Directors
Stock-based compensation
Percentage of options vesting	67.00%
Number of quarterly installments for vesting \| installment	8

Stock-based compensation - Stock option valuation (Details)	3 Months Ended
	Mar. 31, 2022
Assumptions used in the Black-Scholes option-pricing model
Risk-free interest rate	1.64%
Expected term (in years)	5 years
Expected volatility	85.80%

Stock-based compensation - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Number of Shares
Beginning balance	6,532,523
Exercised	(5,684)
Forfeited	(43,527)
Ending balance	6,483,312		6,532,523
Option exercisable	3,779,107
Option unvested	2,704,205
Weighted Averaged Exercise Price
Beginning balance	$ 6.19
Exercised	0.10
Forfeited	6.13
Ending balance	6.20		$ 6.19
Option exercisable	7.85
Option unvested	$ 3.88
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term (in years)	7 years 4 months 24 days		7 years 8 months 12 days
Weighted Average Remaining Contractual Term, option exercisable	6 years 4 months 24 days
Weighted Average Remaining Contractual Term, option unvested	8 years 9 months 18 days
Aggregate Intrinsic Value, beginning balance	$ 490
Aggregate Intrinsic Value, ending balance	435		$ 490
Aggregate Intrinsic Value, option exercisable	$ 435
Fair value per common stock used for calculating intrinsic values	$ 0.74		$ 0.81
Cash received from option exercise under share-based payment arrangements	$ 1	$ 1

Stock-based compensation - Common Stock Awards (Details) - Common Stock Awards - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation
Share Price		$ 3.00
Share-based awards granted	0	112,551
Aggregate fair value of share-based awards granted		$ 0.2
Grant date fair value per share		$ 1.50

Stock-based compensation - Stock-based compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation
Stock-based compensation expense	$ 658	$ 1,621
Research and development expenses
Stock-based compensation
Stock-based compensation expense	240	618
General and administrative expense
Stock-based compensation
Stock-based compensation expense	$ 418	$ 1,003

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Income taxes
Income tax benefits for the net operating losses incurred	$ 0	$ 0

Commitments and contingencies - Operating and Finance Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Commitments and contingencies
Cash balance maintained to secure a letter of credit associated with a real estate lease	$ 421	$ 419
Operating lease right-of-use assets	3,686	4,006
Outstanding operating lease obligations	3,700	4,000
Current operating lease liability	1,719	1,688
Non-current operating lease liability	$ 1,972	$ 2,310
Weighted average discount rate on operating lease liabilities (as a percent)	1.30%
Weighted average lease term remaining on operating lease liabilities (in years)	2 years 6 months

Commitments and contingencies - Others (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Commitments and contingencies
Non-cancellable obligations	$ 8.8
2023 deliverables (remaining nine months)	8.6
2024 deliverables	0.2
Licensing fees from intellectual property licenses	$ 0.3

Net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Numerator:
Net loss	$ (19,680)	$ (17,968)	$ (64,900)
Denominator:
Weighted-average common shares outstanding, basic and diluted	54,720,823	38,603,022
Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock	1,697,000	1,697,000
Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock	15,800,000	4,740,000
Total number of shares used to calculate net loss per share, basic	72,217,823	45,040,022
Total number of shares used to calculate net loss per share, diluted	72,217,823	45,040,022
Net loss per share - basic	$ (0.27)	$ (0.40)
Net loss per share - diluted	$ (0.27)	$ (0.40)
Class A common stock
Denominator:
Number of shares issued for each share of common stock	1
Number of common shares issuable upon conversion of common stock	2,399,517
Series A Convertible Preferred Stock
Denominator:
Number of common stock issued upon conversion of each share of Preferred Stock	1,000
Number of common stock issuable upon conversion of convertible preferred stock	1,697,000
Series A -1 Convertible Preferred Stock
Denominator:
Number of common stock issued upon conversion of each share of Preferred Stock	1,000
Number of common stock issuable upon conversion of convertible preferred stock	15,800,000

Net loss per share - Antidilutive securities (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Anti-dilutive securities
Anti-dilutive shares	6,483,312	4,298,946
Options
Anti-dilutive securities
Anti-dilutive shares	6,483,312	4,298,946

Subsequent Events (Details) - Subsequent event	1 Months Ended
Subsequent Events (Details) - Subsequent event	Apr. 30, 2023 installment $ / shares shares
Subsequent Events
Granted	2,102,100
Exercise price \| $ / shares	$ 1.00
Vesting period	4 years
Inducement Plan 2023
Subsequent Events
Stock reserved for future issuance	500,000
Vesting upon first anniversary
Subsequent Events
Percentage of options vesting	25.00%
Vesting in equal quarterly installments
Subsequent Events
Percentage of options vesting	75.00%
Number of quarterly installments for vesting \| installment	12